Basket cover image
9 handpicked stocks

Made in India

Say namaste to a collection of promising Indian companies carefully selected by our professional analysts. These stocks represent opportunities in the world's most populous nation as it grows toward becoming the third-largest global economy.

stock
stock
stock
stock
stock
stock
stock
stock
stock
Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at मई 15

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

INFY

Infosys Ltd.

INFY

Current price

$16.60

IBN

ICICI Bank Ltd.

IBN

Current price

$32.88

HDB

HDFC Bank Ltd.

HDB

Current price

$74.86

About This Group of Stocks

1

Our Expert Thinking

India's massive 1.4 billion population and rapid economic growth create a perfect environment for business expansion. Our analysts selected these companies as they're positioned to benefit from India's projected rise to become the world's third-largest economy by 2035.

2

What You Need to Know

This collection features companies across various sectors including banking, IT, healthcare, and travel. These stocks offer exposure to India's growing economy, technological innovation, and increasing internet penetration, with the digital services industry expected to reach $350 billion by 2025.

3

Why These Stocks

These companies were handpicked because they're established leaders in their industries with strong positions in India's expanding markets. From IT giants like Infosys and Wipro to financial leaders like ICICI Bank, these stocks represent access to India's bright economic future.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+29.22%

Group Performance Snapshot

29.22%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 29.22% over the next year.

6 of 9

Stocks Rated Buy by Analysts

6 of 9 assets in this group are rated Buy by professional analysts.

4.8% vs 4%

Group Growth vs Bank interest

This group averaged a 4.8% return last month, beating the typical 4% bank rate.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🚀

Rise of a Superpower

India is projected to become the world's third-largest economy by 2035. These companies are positioned to grow alongside the nation's expanding $10 trillion economic journey.

💻

Tech Boom Underway

India's IT and digital services industry is expected to reach $350 billion by 2025. Companies like Infosys and Wipro are at the forefront of this technological revolution.

🌏

1.4 Billion Customers

As the world's most populous nation, India offers these companies an enormous domestic market. Their growing middle class represents one of the largest consumer opportunities on the planet.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.